Company Overview and News

Torian Resources identifies shallow gold mineralisation at Malcolm project

Torian Resources Ltd’s (ASX:TNR) drilling results from its Dover Castle South prospect in Western Australia feature relatively high-grade near surface gold mineralisation.
Upvote Downvote

Torian Resources to commence drilling at the Malcolm gold project

Torian Resources Ltd (ASX:TNR) has started preparations for its next drilling program at the Calypso target, at its Malcolm project located circa 25 kilometres southeast of Leonora in Western Australia.
Upvote Downvote

Torian Resources to lift cash balance for acquisition

Torian Resources (ASX:TNR) has been granted a trading halt by the ASX, pending details of a capital raising.
Upvote Downvote

Torian Resources has an acquisition on the table

Torian Resources Ltd (ASX:TNR) has some interesting news to come this week, in the form of a material acquisition.
Upvote Downvote

Torian Resources Ltd drills gold in Western Australia

Torian Resources Ltd (ASX:TNR) has received positive initial drill results, including 12 metres at 2.44 g/t gold from 36 metres, at Target 18 in the Zuleika JV Project in Western Australia. Torian’s drilling program for FY2017 will see phase 1 exploration completed in several areas, with two priority areas - Targets 18 and 19 to receive 15,000 metres of rotary air blast drilling. The objective of this drilling program is to follow up various historic intersections from the 1980s and 1990s.
Upvote Downvote

Torian Resources Ltd begins drilling to find more gold zones at Zuleika

Torian Resources Ltd (ASX:TNR) has commenced Phase 1 rotary air blast drilling at Targets 18 and 19 at the Zuleika JV Project in the Goldfields region of Western Australia. The drilling will target two areas of gold mineralisation previously identified, with circa 15,000 metres of drilling planned. The objective of this drilling program is to follow up various historic intersections from the 1980s and 1990s.
Upvote Downvote

Torian Resources Ltd to drill in region of gold giants

Torian Resources Ltd (ASX:TNR) has outlined plans to drill in a region where there are major gold discoveries including those of Evolution Mining Ltd (ASX:EVN) Northern Star Resources Ltd (ASX:NST) and Zijin Mining Group Ltd in the Zuleika Shear region of Western Australia. Torian’s managing director’s Matthew Sullivan has also been involved in discovering a number of large gold mines in the Goldfields Region including Kanowna Belle and East Kundana.
Upvote Downvote

Torian Resources Ltd bags $3.3M from oversubscribed placement

Torian Resources Ltd (ASX:TNR) will push ahead with its Goldfield project after completing a $3.3 million share placement at $0.185 each, supported by strong demand from institutional investors. Following the capital raising, Torian will commence the second phase of its four phase exploration program at the Zuleika JV in Western Australia along with JV partner Cascade Resources (CVE:CC.H). Torian is one of the most active resource companies in the Goldfields region of Western Australia, completing 8 acquisitions over the past 12 months.
Upvote Downvote

Torian Resources Ltd gets ready to raise for gold exploration

Torian Resources Ltd (ASX:TNR) is focused on four advanced projects in the Goldfields Regions of Western Australia Torian is now heading to market with a capital raising, with the ASX granting a trading halt to prepare. The halt will remain in place until the opening of trade on Wednesday 29th June 2016, or earlier if an announcement is made to the market. Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.
Upvote Downvote

Appendix 3B

Upvote Downvote


Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...